Life stage

Niemann-Pick disease (NPD) — types A, B, and C

Niemann-Pick disease is a group of lysosomal storage disorders historically grouped under one name but representing distinct underlying biology. NPD-A (SMPD1 mutations causing acid sphingomyelinase deficiency) is the severe infantile neuronopathic form — hepatosplenomegaly, cherry-red macular spot, progressive neurodegeneration, and death by 2-3 years of age; the Ashkenazi Jewish founder population carries an overrepresentation. NPD-B (SMPD1 mutations with residual enzyme activity) is the visceral non-neuronopathic form — hepatosplenomegaly, interstitial lung disease, dyslipidemia, thrombocytopenia, variable cherry-red spot, and adult survival possible. NPD-C (NPC1 or NPC2 mutations causing impaired CHOLESTEROL TRAFFICKING — NOT a sphingomyelin enzyme defect) is a lysosomal cholesterol storage disease despite the shared name, with hepatosplenomegaly, progressive neurodegeneration, vertical supranuclear gaze palsy as a pathognomonic finding, cataplexy, dystonia, ataxia, cognitive decline, and adult-onset psychiatric presentation possible. Standard of care transformed 2022-2024: OLIPUDASE ALFA (XENPOZYME, Sanofi Genzyme) FDA-APPROVED AUGUST 2022 for NPD-A and NPD-B non-CNS manifestations — recombinant acid sphingomyelinase, IV every 2 weeks, via ASCEND and ASCEND-Peds; MIGLUSTAT (ZAVESCA, Actelion/J&J) EMA-APPROVED 2009 for NPD-C — glucosylceramide synthase inhibitor substrate reduction therapy; NOT FDA-approved for NPD-C, off-label in US; September 2024 brought landmark same-day FDA approval pair for NPD-C: MIPLYFFA (arimoclomol, Zevra Therapeutics) — heat shock protein co-inducer combination with miglustat — and AQNEURSA (N-acetyl-L-leucine, IntraBio). HP-β-CD investigational. AAV gene therapy programs (Lysogene and others) in trials. Patient infrastructure: NATIONAL NIEMANN-PICK DISEASE FOUNDATION (NNPDF, nnpdf.org) US, NIEMANN-PICK UK, INTERNATIONAL NIEMANN-PICK DISEASE ALLIANCE (INPDA), and the ARA PARSEGHIAN MEDICAL RESEARCH FOUNDATION (Notre Dame coach's pediatric NPD-C legacy). Ninety-ninth deliberate non-elevation.

What changes during this transition

Niemann-Pick disease arrives in the peptide-companion library along four predictable community-curiosity vectors, each of which fails on the same load-bearing reality: this is a group of three editorially distinct lysosomal storage disorders sharing a name, with a genuinely transformed 2022-2024 standard-of-care landscape, multi-jurisdictional regulatory reality, and an AAV gene-therapy frontier — and peptides do not address any of the load-bearing axes. The editorial distinction across NPD-A, NPD-B, and NPD-C is load-bearing. NPD-A is SMPD1-driven severe infantile neuronopathic sphingomyelinase deficiency, fatal by 2-3 years, with Ashkenazi Jewish founder population overrepresentation. NPD-B is SMPD1-driven visceral non-neuronopathic disease with residual enzyme activity — hepatosplenomegaly, ILD, dyslipidemia, thrombocytopenia — and the FDA approval of olipudase alfa (Xenpozyme, Sanofi Genzyme) in August 2022 transformed the adult survival trajectory. NPD-C is NPC1- or NPC2-driven impaired cholesterol trafficking — a lysosomal cholesterol storage disease, NOT a sphingomyelin enzyme defect, despite the shared name — with multi-system phenotype including VSGP pathognomonic, cataplexy, dystonia, ataxia, cognitive decline, and adult-onset psychiatric presentation possible. The September 2024 same-day FDA approvals of Miplyffa (arimoclomol, Zevra Therapeutics) and Aqneursa (N-acetyl-L-leucine, IntraBio) are the editorial center of gravity for NPD-C, sitting alongside the 2009 EMA approval of miglustat (Zavesca, US off-label) and the August 2022 FDA approval of olipudase alfa (Xenpozyme) for NPD-A and NPD-B non-CNS. No peptide in the Juno library has a discovery-card-defensible Niemann-Pick case. Ninety-ninth deliberate non-elevation.

Important caveat

Niemann-Pick disease is metabolic-specialist-managed — your inherited metabolic disorders specialist (and, for NPD-B, pulmonology for ILD management and hematology for thrombocytopenia; for NPD-C, pediatric or adult neurology for neurologic-progression management) leads diagnosis, subtype determination, and disease-modifying-therapy selection. **THE THREE SUBTYPES ARE EDITORIALLY DISTINCT — NPD-A (SMPD1 severe infantile neuronopathic, fatal by 2-3 years), NPD-B (SMPD1 with residual activity, visceral non-neuronopathic, hepatosplenomegaly + ILD + dyslipidemia + thrombocytopenia, adult survival possible), and NPD-C (NPC1 or NPC2 IMPAIRED CHOLESTEROL TRAFFICKING — NOT a sphingomyelin enzyme defect — a lysosomal CHOLESTEROL storage disease, VERTICAL SUPRANUCLEAR GAZE PALSY pathognomonic, adult-onset psychiatric presentation possible).** **STANDARD-OF-CARE TRANSFORMED 2022-2024**: **OLIPUDASE ALFA (XENPOZYME, Sanofi Genzyme) FDA-APPROVED AUGUST 2022 for NPD-A and NPD-B non-CNS manifestations** — recombinant acid sphingomyelinase IV every 2 weeks (does NOT cross BBB so does not treat CNS in NPD-A but transforms visceral disease in NPD-B). **MIGLUSTAT (ZAVESCA, Actelion/J&J) EMA-APPROVED 2009 for NPD-C** — substrate reduction therapy; **NOT FDA-approved for NPD-C — off-label in US**; **MULTI-JURISDICTIONAL REALITY — EMA recognition predates FDA by 15 years**. **MIPLYFFA (arimoclomol, Zevra Therapeutics) FDA-APPROVED SEPTEMBER 2024 for NPD-C** — heat shock protein co-inducer combination with miglustat. **AQNEURSA (N-acetyl-L-leucine, IntraBio) FDA-APPROVED SEPTEMBER 2024 for NPD-C — SAME-DAY LANDMARK APPROVAL with Miplyffa**. **HP-β-CD** investigational; Mallinckrodt Adrabetadex (VTS-270) failed late-phase development. AAV gene therapy programs in trials. **PEDIATRIC EDITORIAL SENSITIVITY SHARP** — NPD-A is infantile fatal, NPD-C is variable from infantile to adult onset. **ASHKENAZI JEWISH FOUNDER POPULATION** for NPD-A. **PATIENT INFRASTRUCTURE**: **NNPDF (nnpdf.org)** + **Niemann-Pick UK** + **INPDA** + **Ara Parseghian Medical Research Foundation**. **COMMUNITY PEPTIDES Tier 3**: **BPC-157** — 'tissue repair' framing collides with lysosomal accumulation biology. **NMN** — general-aging framing in adult-onset NPD-C + post-Xenpozyme aging NPD-B; no engagement with sphingomyelin or cholesterol trafficking. **GH-AXIS TRIO** — GH/IGF-1 anabolic shift uncharacterized in lysosomal storage disease. **TESAMORELIN Rule 6 SHARPEST** — HIV-LD FDA label does NOT propagate. **SEMAGLUTIDE**: NPD-B carries ILD + thrombocytopenia + dyslipidemia overlay; NPD-C carries neurologic-progression overlay. **NO Juno library peptide is surfaced as a Niemann-Pick discovery card — 99th deliberate non-elevation**. **RED FLAGS**: respiratory destabilization in adult NPD-B; bleeding signal in thrombocytopenic NPD-B; neurologic-progression acceleration in NPD-C; psychiatric prodrome in adult with hepatosplenomegaly (adult-onset NPD-C under-recognized).

No peptides in our current library are editorially mapped to this stage. The "What changes" section above explains why — usually because non-peptide interventions are the primary lever, or because the safety floor for adding a peptide during this transition is high enough that we don’t recommend one.

Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.